Home' Australian Pharmacist : Australian Pharmacist January 2012 Contents 80
Australian Pharmacist January 2012 I ©Pharmaceutical Society of Australia Ltd.
• indacaterol provides similar
improvement in lung function
over 12 weeks in comparison with
tiotropium (Trough FEV1 1.44L vs 1.43L,
• Rapid onset on action within 5 minutes
of administration (observed after the
first dose), which lasts for 24 hours2,6
• Significantly greater improvement
in breathlessness over 12 weeks
compared to tiotropium (TDI total
scores at week 12 showed a greater
reduction in dyspnoea with indacaterol
than with tiotropium – LSM + SE
2.01 + 0.178 and 1.43 + 0.178 points,
respectively; p<0.001 for the treatment
difference of 0.58)5
• More days without rescue medication
over 12 weeks in comparison with
tiotropium (46.1% + 1.65, n=725 vs.
41.4% + 1.64, n=738; p=0.004)5
• Improvements in health-related quality
of life (including improved health status
and reduced dyspnoea) compared to
Indacaterol is administered using the
Breezhaler device, which provides
patients with dosing feedback. Patients
can hear the device working, feel the
product which was inhaled and see the
1. Official PBS notification letter to Novartis. Received 4 Nov 2011.
2. Onbrez Breezhaler Product Information.
3. Kornmann, et al. Once-daily indacaterol vs twice-daily
salmeterol for COPD: a placebo-controlled comparison.
Eur Respir J 2011;37:273–9 .
4. Donohue,et al. Once-daily bronchodilators for chronic
obstructive pulmonary disease: Indacaterol versus tiotropium.
Am J Respir Crit Care Med 2010;182:155–62.
5. Buhl et al. Blinded, doubledummy, 12-week comparison of once
daily indacaterol and tiotropium in COPD. Eur Respir J, 2011
6. Balint B, et al. Onset of action of indacaterol in patients with
COPD: Comparison with salbutamol and salmeterol fluticasone.
Int J Chron Obstruct Pulmon Dis 2010;5:311–8 .
7. Pavkov R et al. Characteristics of a capsule based dry powder
inhaler for the delivery of indacaterol. Curr Med Res Opin
Rosehip has been added to the (generic)
to the Arthritis Australia Complementary
Therapies Information Sheet. Professor
Marc Cohen Head of Complementary
Medicine at RMIT University said,
‘Many people with Arthritis turn to
complementary therapies to relieve their
symptoms but navigating the myriad of
natural remedies can be confusing. It is
not often that a natural remedy can be
recommended based on well conducted
clinical studies with consistently positive
results. Rosehip is one such remedy that
has proven to be both safe and efficacy in
‘ The Arthritis Australia Complementary
Therapies Information Sheet provides
clear and concise information on which
type of complementary therapy could
be effective for your Arthritis. Safe
and effective natural remedies such as
Rosehip should be considered as first-line
therapies for arthritis’.
Rose-Hip Vital Director, Colin Diamond
said the addition of Rosehip to the
respected list added to mounting clinical
and scientific evidence for Rosehip as
a natural anti-inflammatory. He said
the addition of Rosehip to the Arthritis
Australia information sheet would
help sufferers find effective relief for
their Arthritis and is gaining significant
interest from the international medical
community for the natural relief of both
osteoarthritis and rheumatoid arthritis.
Rosehip studies specific to osteoarthritis
(OA) have shown promising results,
including a study published in
Scandinavian Journal Of Rheumatology
(2005) showing that 82% of OA patients
reported a reduction in pain after three
weeks of treatment with a patented
rosehip powder.1 In addition to the
results for OA, a study published in
Phytomedicine (2010) showed that
rosehip powder in a patented form may
be effective for controlling some of the
symptoms of rheumatoid arthritis.2
1. Winther K, A Powder Made From The Seeds and Shells Of A
Rosehip Subspecies (Rosa Canina L.) Reduces Symptoms Of
Knee And Hip Osteoarthritis. The Scandinavian Journal of
Rheumatology. 2005 Aug. At: www.arthritisaustralia.com.au/
2. Willich SN, et al. Rosehip herbal remedy in patients with
Rheumatoid Arthritis – a randomised controlled trial.
Phytomedicine 2010 Feb.
Items in the Product news section are prepared from information provided by the companies named in
each item. They are included for the information of PSA members. It is up to the individual member to use
their professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither
endorses nor confirms claims made in the items. (Where provided by the company references citing
evidence are included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest
to all pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy
profession or the professional practice of pharmacy. Advertising which does not comply with this policy will
be refused. It is the responsibility of the advertisers to comply with the relevant Commonwealth and State
law. Advertising does not constitute an endorsement by PSA of the claims, products or services.
Australia’s No.1 pharmacy title – read by more than 7 out of 10 community pharmacists.
The most valued and used pharmacy title by community pharmacists for clinical information,
continuing education, prescription medicines, scheduled medicines, patient counselling, plus
performs well for S2, S3.
The CPD program is followed by more than 7600 pharmacists and each article receives more
than 2700 assessments each month from pharmacists enhancing their knowledge.
The journal offers the best readers and the most powerful space for your advertising. This is
evident by the high quality readership:
Phone: 02 9988 4689
Phone: 02 9547 3001
► Offers highest community pharmacist readership (71%)
► The most regularly read pharmacy title
► 60% of recipients read every issue
► 79% of recipients read 4 to 6 of the last six issues
► Circulation 14,084 cab September 2011
Links Archive Australian Pharmacist February 2012 December 2011 Navigation Previous Page Next Page